Amicus Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2002-01-01
- Employees
- 517
- Market Cap
- $3.3B
- Website
- http://www.amicusrx.com
- Introduction
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.
A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy
- Conditions
- Gaucher Disease, Type 1Type 1 Gaucher DiseaseGaucher Disease
- Interventions
- First Posted Date
- 2007-02-09
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT00433147
Study to Evaluate Blood Cell Lines From Patients With Gaucher Disease
- Conditions
- Gaucher Disease
- First Posted Date
- 2006-07-12
- Last Posted Date
- 2010-08-19
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT00351156
- Locations
- 🇺🇸
University Research Foundation for Lysosomal Storage Diseases, Inc., Coral Springs, Florida, United States
🇺🇸National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, United States
🇺🇸New York University School of Medicine, Neurogenetics Department, New York, New York, United States
A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease
- First Posted Date
- 2006-03-20
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 9
- Registration Number
- NCT00304512
A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease
- First Posted Date
- 2006-01-31
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 4
- Registration Number
- NCT00283959
A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease
- First Posted Date
- 2006-01-31
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 5
- Registration Number
- NCT00283933
A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 9
- Registration Number
- NCT00214500